Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 9-valent HPV Vaccine in Chinese Males
NCT05518201Phase 1Completed
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, penile cancer, anal cancer and 1 more (4 arms), sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoints: Number of subjects with Adverse Events at Month 7 and Number of subjects with Severe adverse events at Month 12. Started Sep 2022; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionpenile canceranal cancergenital warts
Beyond the preview
Go deeper on NCT05518201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518201.